GLP-1 Medications for Women Over 40: What Changes and What to Expect

Reviewed by Donald L. Gates, MD — Bariatric Medicine, practicing since 1999

Women over 40 who struggle with weight gain often hear the same dismissive explanations: slower metabolism, hormones, age. These explanations are not wrong — they are just incomplete. The hormonal transitions that begin in perimenopause fundamentally alter how the body manages fat storage, muscle mass, bone density, and appetite regulation. GLP-1 medications work in this changed physiological environment, and understanding what that means — what to expect, what requires extra attention, and what can genuinely help — is essential for setting realistic goals and getting the best outcome from treatment.

Perimenopause and the Hormonal Shift That Changes Weight

Perimenopause typically begins in the early-to-mid 40s, though it can start earlier, and it is not a single event. It is a multi-year transition during which estrogen and progesterone levels fluctuate erratically before eventually declining. This hormonal chaos has measurable effects on body weight and fat distribution.

Estrogen is not just a reproductive hormone. It plays a significant role in fat metabolism, fat distribution, and energy regulation. As estrogen declines during perimenopause, several things happen that affect weight:

• Central fat redistribution: Fat that was previously distributed in the hips and thighs (the classic gynoid pattern) shifts toward the abdomen. Visceral fat — the metabolically active fat that surrounds abdominal organs — increases. This is a more metabolically harmful fat depot associated with insulin resistance, inflammation, and cardiovascular risk.
• Insulin sensitivity declines: Estrogen has insulin-sensitizing effects. As levels drop, insulin resistance tends to increase, making it easier to gain weight and harder to lose it even at the same caloric intake.
• Sleep disruption: Hot flashes, night sweats, and anxiety-driven insomnia are common in perimenopause. Poor sleep independently drives weight gain through cortisol dysregulation and ghrelin elevation.
• Appetite regulation changes: GLP-1, the hormone that these medications mimic, is produced in the gut in response to food. Some evidence suggests that GLP-1 sensitivity or production may shift during hormonal transitions, though this remains an active area of research.

GLP-1 medications do not replace estrogen, and they do not address all of these mechanisms. But they do meaningfully address appetite dysregulation and, through weight loss, can reduce visceral fat accumulation and improve insulin sensitivity — both of which are significant in this demographic.

Slower Metabolism: What Is Actually Happening

Resting metabolic rate — the number of calories your body burns at rest — declines with age in both sexes, but the decline in women is often accelerated during the perimenopausal transition due to combined effects of hormonal change and muscle mass loss. The typical decline in resting metabolic rate between ages 40 and 60 is approximately 100-200 calories per day — modest in absolute terms but meaningful when accumulated over years.

The metabolic decline is not primarily driven by age itself. It is driven by loss of muscle mass, which is the most metabolically active tissue in the body. Women who maintain or build muscle mass through their 40s and 50s preserve their metabolic rate far better than women who are sedentary.

This is why resistance training is not optional for women over 40 on GLP-1 therapy — it is essential. The medication will reduce appetite and support weight loss. But if muscle mass declines significantly during that process (which it will without resistance stimulus), the metabolic rate drops further, making both maintenance and future weight management harder. Our page on preserving muscle on GLP-1 covers this in full detail.

Bone Density: A Specific Concern for This Population

Rapid weight loss — from any cause, including GLP-1 therapy — can accelerate bone mineral density loss. In women over 40 who are already entering the accelerated bone loss phase that accompanies estrogen decline, this compounds an existing risk.

GLP-1 receptor agonists have been studied for their effect on bone density. The data is reassuring but not fully definitive. Some studies suggest that the weight-loss-associated mechanical unloading (bones carry less weight, so the stimulus for bone density maintenance decreases) may partially offset any direct bone-protective effects of GLP-1 receptor activation.

Practical steps for bone health during GLP-1 therapy in women over 40:

• Calcium: 1,000-1,200mg per day from food and supplementation combined. Dairy, leafy greens, and fortified foods are dietary sources; supplementation may be needed to reach targets.
• Vitamin D: Most adults in the southeastern US are not vitamin D deficient due to sun exposure, but indoor lifestyles and sunscreen use can create gaps. Vitamin D3 supplementation of 1,000-2,000 IU daily is reasonable and inexpensive. Dr. Gates can check your level with a simple blood test.
• Weight-bearing exercise: Resistance training and weight-bearing cardio (walking, jogging, dancing) maintain bone density through mechanical loading. Low-impact activities like swimming and cycling, while excellent for cardiovascular health, do not provide the same bone stimulus.
• DEXA scan consideration: Women over 40 beginning significant weight loss treatment may benefit from a baseline DEXA scan that includes bone mineral density assessment. This provides a reference point and can identify pre-existing osteopenia warranting closer monitoring.

Menstrual Cycle Disruption During Treatment

Rapid weight loss can affect menstrual cycle regularity in perimenopausal women. This happens through several mechanisms: changes in adipose tissue (which produces estrogen) alter circulating estrogen levels; caloric deficit and metabolic stress can affect hypothalamic-pituitary-gonadal axis signaling; and the underlying hormonal fluctuations of perimenopause may be temporarily amplified.

Women on GLP-1 therapy may notice changes in cycle length, flow, or timing. These changes are generally benign and often normalize as weight stabilizes. However, any new or unexpected vaginal bleeding should be evaluated — weight loss and GLP-1 therapy do not cause endometrial pathology, but they also should not be used to explain away bleeding that warrants investigation.

Fertility consideration: weight loss can restore or improve fertility in women with PCOS and obesity-related anovulation. Women who are not planning pregnancy should ensure they are using reliable contraception even if their cycle has been irregular — improved ovulatory function can occur before cycle regularity is restored.

HRT Compatibility

Many women over 40 asking about GLP-1 therapy are also considering, or already using, hormone replacement therapy (HRT). The good news here is straightforward: there are no known clinically significant interactions between GLP-1 receptor agonists and standard HRT formulations (oral estrogens, transdermal estrogens, progesterone). Patients can generally continue HRT while on GLP-1 therapy without modification.

HRT itself may have modest effects on body composition during weight loss — some evidence suggests estrogen supplementation during caloric deficit may partially attenuate the muscle loss that accompanies rapid weight reduction. This is not a strong enough effect to rely on instead of resistance training, but it is a potential additive benefit for women who have clinical indications for HRT.

Decisions about HRT are complex and individualized — outside the scope of weight management alone. Dr. Gates can discuss the interaction of HRT with GLP-1 treatment in the context of your overall health history.

Thyroid Screening

Thyroid dysfunction — both hypothyroidism and hyperthyroidism — is significantly more common in women than in men and increases in prevalence after age 40. Untreated hypothyroidism produces weight gain, fatigue, constipation, cold intolerance, and depression. These symptoms can mimic or compound GLP-1 side effects and can blunt weight loss response if untreated.

Before starting GLP-1 therapy, Dr. Gates screens for thyroid dysfunction as part of the initial laboratory evaluation. Thyroid-stimulating hormone (TSH) is included in the standard labs. Patients with known thyroid conditions and those on thyroid replacement therapy (levothyroxine) require monitoring to ensure thyroid levels remain optimized during the weight loss period, as weight change can affect thyroid hormone requirements.

GLP-1 medications carry a theoretical warning regarding medullary thyroid carcinoma risk, derived from animal studies using high doses over prolonged periods. In humans, no causal link has been established, but patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) should not use GLP-1 receptor agonists. Dr. Gates reviews this history during the initial evaluation.

What Scale Solutions Offers for Women Over 40

Dr. Gates has been managing weight in women across the full adult age spectrum since 1999. The approach at Scale Solutions for women over 40 includes:

• Initial labs that include thyroid function, metabolic panel, lipid panel, and hemoglobin A1c
• Assessment of menopausal status and HRT history as part of the intake evaluation
• Protein and resistance training guidance specific to muscle and bone preservation in the perimenopausal context
• Calcium and vitamin D review and supplementation guidance
• Monitoring of body composition markers (calf circumference, grip strength) throughout treatment
• DEXA referral for patients with bone density concerns
• Spanish-language consultations available for patients who are more comfortable in Spanish

For information specific to GLP-1 therapy and menopause, see our dedicated page on GLP-1 and menopause. For more on the medication itself, see the semaglutide overview. If you are ready to discuss whether GLP-1 therapy is appropriate for your specific situation, learn more about Dr. Gates’s approach on the about Dr. Gates page.

This page is for informational purposes only and is not medical advice. Consult Dr. Gates or another qualified clinician before starting any treatment.